Dosage research on CJC-1295 + Ipamorelin Blend

Preclinical research dose ranges

In published preclinical research on combined CJC-1295 No DAC and Ipamorelin administration, the per-component dose ranges have followed the previously-characterised single-compound conventions. The CJC-1295 No DAC component preclinical dose range has fallen in the 1 to 50 microgram per kilogram subcutaneous range; the Ipamorelin component preclinical dose range has fallen in the 1 to 100 microgram per kilogram subcutaneous range.

Combined-administration pharmacology studies have characterised synergistic GH-pulse-amplitude effects of the combined dosing relative to either compound alone at matched per-component doses. The published mechanistic rationale is that GHRH-receptor activation (by the CJC-1295 No DAC component) and ghrelin-receptor activation (by the Ipamorelin component) drive GH release through independent endogenous pathways, producing synergy rather than redundancy.

The Ronin catalog supplies the blend at a 1:1 fixed ratio (5 mg CJC-1295 No DAC + 5 mg Ipamorelin per 10 mg vial). Investigators interested in distinguishing per-component contributions to combined effects would need separate single-compound vials rather than the pre-combined blend formulation.

Dose-response considerations from the published literature

The published combined CJC-1295 / Ipamorelin literature has reported synergistic dose-response characteristics on GH-pulse amplitude across the per-component microgram-per-kilogram dose ranges characterised for each compound alone. The synergy magnitude varies with the specific per-component doses chosen and with the time-course measurement window.

No Phase 1 or Phase 2 dose-ranging trial of the combined CJC-1295 / Ipamorelin blend has appeared in the indexed clinical-trial literature at the time of writing. The research community continues to rely on the per-component literatures and on combined-administration pharmacology for dose-design inference. The Walker and colleagues line of work characterised combined GHRH-receptor + ghrelin-receptor synergy across the per-component dose ranges in rat pharmacology; investigators applying that mechanism in research-protocol design typically use the per-component dose anchors rather than the blend formulation when isolating per-component contributions is the experimental requirement.

Reconstitution math and per-vial dose calculation

A 10 mg lyophilised CJC-1295 + Ipamorelin blend vial (5 mg of each component) reconstituted with 2 mL of bacteriostatic water yields a stock concentration of 5 mg per mL of combined formulation (2.5 mg per mL of each component). The reconstitution volume can be adjusted to alter the stock concentration: 1 mL of bacteriostatic water per vial yields a 10 mg per mL combined-formulation stock (5 mg per mL of each component) for protocols requiring higher per-aliquot dose amounts. From this stock, a research aliquot of 0.1 mL contains 500 micrograms of combined formulation (250 micrograms of each component). Researchers working with the per-component microgram-per-kilogram dose ranges further dilute the stock to a working concentration appropriate to the model and the body weight of the animal subject. Refrigerated storage at 2 to 8 degrees Celsius, protected from light, is the standard handling practice.

Research-protocol design considerations

Protocol-design choices in the published CJC-1295 / Ipamorelin combined literature reflect several recurring considerations. The fixed-ratio formulation is the central protocol-design decision: investigators interested in the contribution of each component to the combined effect would need to use separate vials (CJC-1295 No DAC alone, Ipamorelin alone, combination, placebo) as separate arms rather than the pre-combined blend formulation.

Route of administration in the published combined-administration literature uses subcutaneous injection matching the per-component conventions. Acute single-dose protocols are standard for GH-pulse-amplitude characterisation; multi-day and multi-week protocols appear in IGF-I time-course and body-composition endpoint studies.

The complementary-pathway mechanism (GHRH-receptor on one side, ghrelin-receptor on the other) is the canonical mechanistic rationale for the blend formulation. Protocol designs comparing the blend to single-compound dosing should account for this mechanistic complementarity and for the synergistic dose-response profile that the per-component-alone literatures do not predict.

References

1. Jetté L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats. Endocrinology, 2005. [PMID 15817669]
2. Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. Journal of Clinical Endocrinology and Metabolism, 2006. [PMID 16352683]
3. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998. [PMID 9849822]
4. Hansen BS et al. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues. Drug Metabolism and Disposition, 1999. [PMID 9879640]
5. Bowers CY. Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents. Journal of Pediatric Endocrinology and Metabolism, 1997. [PMID 9238854]